Said Darwazah, Chairman and Chief Executive, said: "I am delighted that Dr Kirby has agreed to join our Board. She brings a wealth of pharmaceutical, international, strategic, and listed company experience. She has a strong track record from her senior executive and board-level roles, and complements our culture and style perfectly. I am confident that she will enhance the capabilities of the Board, and that we are now in an even stronger position to lead our company going forward."

Dr Pamela Kirby

Dr Pamela Kirby was CEO of Quintiles Transnational Corp and has held senior executive positions in F Hoffmann-La Roche Ltd and AstraZeneca plc. Dr Kirby has chaired Oxford Immunotec Ltd and was senior independent director of Informa plc. Dr Kirby has previously held non-executive director positions with Smith & Nephew plc, Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals Corp.

Dr Kirby is chairman of Scynexis Inc and a non-executive director of DCC plc and Victrex plc.

Dr Kirby holds a first-class Bachelor of Science degree in Pharmacology and a PhD in Clinical Pharmacology from the University of London.